Cargando…

Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series

Acute viral pharyngitis (AVP) is a common respiratory illness affecting many individuals. Despite symptomatic treatment management of AVP, therapies are lacking to target a broad spectrum of viruses and the inflammatory nature of the disease. Available for many years, Chlorpheniramine Maleate (CPM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesch, Mari L, Dasgupta, Rahul, Khawaja, Uzzam Ahmed, Sanchez-Gonzalez, Marcos, Franck, Rahaghi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970260/
https://www.ncbi.nlm.nih.gov/pubmed/36860214
http://dx.doi.org/10.7759/cureus.34310
_version_ 1784897886968872960
author Tesch, Mari L
Dasgupta, Rahul
Khawaja, Uzzam Ahmed
Sanchez-Gonzalez, Marcos
Franck, Rahaghi
author_facet Tesch, Mari L
Dasgupta, Rahul
Khawaja, Uzzam Ahmed
Sanchez-Gonzalez, Marcos
Franck, Rahaghi
author_sort Tesch, Mari L
collection PubMed
description Acute viral pharyngitis (AVP) is a common respiratory illness affecting many individuals. Despite symptomatic treatment management of AVP, therapies are lacking to target a broad spectrum of viruses and the inflammatory nature of the disease. Available for many years, Chlorpheniramine Maleate (CPM), is considered a low-cost and safe first-generation antihistamine displaying antiallergic, anti-inflammatory, and as of recently, identified as a broad-spectrum antiviral agent with activity against influenzas A/B viruses and SARS-CoV-2. Efforts have been made to identify repurposed drugs with favorable safety profiles that could significantly benefit the treatment of COVID-19-induced symptoms. The present case series highlights three patients in which a CPM-based throat spray was used to alleviate the symptoms of COVID-19-induced AVP. The CPM throat spray was associated with significant improvements in patient symptoms after approximately three days of use as opposed to the typical five to seven days reported elsewhere. While AVP is a self-limited syndrome and usually improves without pharmaceutical therapy, CPM throat spray may significantly reduce the overall time that the patient has symptoms. Additional clinical studies to evaluate the efficacy of CPM for the treatment of COVID-19-induced AVP are warranted.
format Online
Article
Text
id pubmed-9970260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-99702602023-02-28 Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series Tesch, Mari L Dasgupta, Rahul Khawaja, Uzzam Ahmed Sanchez-Gonzalez, Marcos Franck, Rahaghi Cureus Infectious Disease Acute viral pharyngitis (AVP) is a common respiratory illness affecting many individuals. Despite symptomatic treatment management of AVP, therapies are lacking to target a broad spectrum of viruses and the inflammatory nature of the disease. Available for many years, Chlorpheniramine Maleate (CPM), is considered a low-cost and safe first-generation antihistamine displaying antiallergic, anti-inflammatory, and as of recently, identified as a broad-spectrum antiviral agent with activity against influenzas A/B viruses and SARS-CoV-2. Efforts have been made to identify repurposed drugs with favorable safety profiles that could significantly benefit the treatment of COVID-19-induced symptoms. The present case series highlights three patients in which a CPM-based throat spray was used to alleviate the symptoms of COVID-19-induced AVP. The CPM throat spray was associated with significant improvements in patient symptoms after approximately three days of use as opposed to the typical five to seven days reported elsewhere. While AVP is a self-limited syndrome and usually improves without pharmaceutical therapy, CPM throat spray may significantly reduce the overall time that the patient has symptoms. Additional clinical studies to evaluate the efficacy of CPM for the treatment of COVID-19-induced AVP are warranted. Cureus 2023-01-28 /pmc/articles/PMC9970260/ /pubmed/36860214 http://dx.doi.org/10.7759/cureus.34310 Text en Copyright © 2023, Tesch et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Tesch, Mari L
Dasgupta, Rahul
Khawaja, Uzzam Ahmed
Sanchez-Gonzalez, Marcos
Franck, Rahaghi
Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title_full Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title_fullStr Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title_full_unstemmed Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title_short Chlorpheniramine Maleate Throat Spray for the Treatment of COVID-19-Induced Acute Viral Pharyngitis: Case Series
title_sort chlorpheniramine maleate throat spray for the treatment of covid-19-induced acute viral pharyngitis: case series
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970260/
https://www.ncbi.nlm.nih.gov/pubmed/36860214
http://dx.doi.org/10.7759/cureus.34310
work_keys_str_mv AT teschmaril chlorpheniraminemaleatethroatsprayforthetreatmentofcovid19inducedacuteviralpharyngitiscaseseries
AT dasguptarahul chlorpheniraminemaleatethroatsprayforthetreatmentofcovid19inducedacuteviralpharyngitiscaseseries
AT khawajauzzamahmed chlorpheniraminemaleatethroatsprayforthetreatmentofcovid19inducedacuteviralpharyngitiscaseseries
AT sanchezgonzalezmarcos chlorpheniraminemaleatethroatsprayforthetreatmentofcovid19inducedacuteviralpharyngitiscaseseries
AT franckrahaghi chlorpheniraminemaleatethroatsprayforthetreatmentofcovid19inducedacuteviralpharyngitiscaseseries